Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma

Fig. 6

γ/δ T cells maintain their intrinsic cytolytic activity against Daudi cells after receptor transfection. ZA-activated γ/δ T cells (a + b; closed symbols), OKT3-stimulated MACS-isolated γ/δ T cells (a + b; open symbols), OKT3-activated PBMC (c + d; closed symbols), and OKT3-stimulated MACS-isolated CD8+ T cells (c + d; open symbols) were expanded and electroporated as described above (Figs. 1 and 2). Mock-electroporated T cells (dotted lines; mock) served as controls. After over-night culture, the cytolytic capacity of TCR- (a + c) and CAR- (b + d) transfected T cells towards Daudi cells was examined at indicated effector to target ratios in a standard 4–6 h chromium release assay. The percentage of lysed cells was calculated. Data are presented as means ± SEM derived from 3 to 5 independent experiments, each performed in technical triplicate. P-values calculated by unpaired Student’s t-test are presented in Additional file 1: Table S7

Back to article page